Methods of treating ttr amyloidosis using ag10
AssigneeEidos Therapeutics, Inc.
InventorsUma SINHA, Satish RAO
Life of this patent
Estimating the term…
Abstract
Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects
Claims17
-89. (canceled)
A method of treating transthyretin amyloidosis (ATTR) cardiomyopathy in a subject in need thereof, the method comprising administering to a subject in need thereof a total daily dosage of about 1,600 milligrams (mg) of Compound 1, having the Formula:
- in HCl salt form, wherein Compound 1 is administered twice daily, and wherein the administration of Compound 1
- (1) reduces the decline in a six-minute walk test compared to subjects not receiving treatment;
- or
- (2) improves the six-minute walk test performance of the subject compared to a baseline distance measured prior to treatment with Compound 1.
A method of slowing the progression of transthyretin amyloidosis (ATTR) cardiomyopathy in a subject in need thereof, the method comprising administering to a subject in need thereof a total daily dosage of about 1,600 milligrams (mg) of Compound 1, having the Formula:
- in HCl salt form, wherein Compound 1 is administered twice daily, and wherein the administration of Compound 1 reduces the decline in a six-minute walk test performance of the subject compared to subjects not receiving treatment.
A single unit dosage comprising about 10-1,000 milligrams (mg) of Compound 1, having the formula:
- or a pharmaceutically acceptable salt thereof
Dependencies are inferred from the claim text.